Trial Profile
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2018
Price :
$35
*
At a glance
- Drugs Ilorasertib (Primary) ; Ilorasertib (Primary) ; Carboplatin; Docetaxel
- Indications Colorectal cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories; AbbVie
- 19 Mar 2018 Status changed to discontinued as per results published in the British Journal of Cancer.
- 19 Mar 2018 Results of analysis of prospectively collected data of three monotherapy arms assessing safety, efficacy, pharmacokinetics and pharmacodynamics published in the British Journal of Cancer
- 06 Jun 2017 Results of a pharmaco-kinetics/dynamics evaluation from NCT02540876 and NCT01110486 trials presented at the 53rd Annual Meeting of the American Society of Clinical Oncology